Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Thrombosis and Thrombolysis
Literature
1.
Linkin LA, Dans AL, Moores LK et al. (2012) Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis. american college of chest physicians evidence-based clinical practice guidelines. Chest 141(2):e495S–e530SCrossRef
2.
Cuker A (2011) Heparin-induced thrombocytopenia: present and future. J Thromb Thrombolysis 31(3):353–366CrossRefPubMed
3.
Nanwa N, Mittmann N, Knowles S et al (2011) The direct medical costs associated with suspected heparin-induced thrombocytopenia. Pharmacoeconomics 29(6):511–520CrossRefPubMed
4.
Smythe MA, Koerber JM, Fitzgerald M et al (2008) The financial impact of heparin-induced thrombocytopenia. Chest 134(3):568–573CrossRefPubMed
5.
Ritchie BM, Connors JM, Sylvester KW (2017) Comparison of an Ig-G-specific enzyme-linked immunosorbent assay cutoff of 0.4 versus 0.8 and 1.0 optical density units for heparin-induced thrombocytopenia. Clin Appl Thromb Haemost 23(3):282–286CrossRef
6.
Harada MY, Hoang DM, Zaw AA et al (2016) Overtreatment of heparin-induced thrombocytopenia in the surgical ICU. Crit Care Med 45(1):28–34CrossRef
7.
Sadik ZG, Jennings DL, Nemerovski CW et al (2015) Impact of platelet functional assays on the cost of treating suspected heparin-induced thrombocytopenia. J Pharm Pract 28(4):398–403CrossRefPubMed
8.
Newman TB, Browner WS, Cummings SR, Hulley SB (2007) Chapter 12: designing studies of medical tests. In: Designing clinical research, 3rd edn. Lippincott Williams & Wilkins, Philadelphia, PA, 183–205
9.
Chan CM, Woods CJ, Warkentin TE et al (2015) The role for optical density in heparin-induced thrombocytopenia: a cohort study. Chest 148(1):55–61CrossRefPubMed
Metadata
Title
Development of an algorithm for the systematic evaluation of patients with suspected heparin-induced thrombocytopenia
Authors
Julie Thomson
Philip Kuriakose
Long To
Michael Peters
James Kalus
Publication date
01-04-2019
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 3/2019
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-019-01828-7

Other articles of this Issue 3/2019

Journal of Thrombosis and Thrombolysis 3/2019 Go to the issue

ReviewPaper

Evaluation of direct oral anticoagulants for the treatment of cancer-associated thrombosis: an update

OriginalPaper

Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function

OriginalPaper

Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial

BriefCommunication

Thrombin generation profile in non-thrombotic factor V Leiden carriers

OriginalPaper

Shorter hospital stays in epistaxis patients with atrial fibrillation when taking rivaroxaban or apixaban versus phenprocoumon

OriginalPaper

Adjusted versus actual body weight dosing of 4-factor prothrombin complex concentrate in obese patients with warfarin-associated major bleeding
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits